Home
Our News
Following decision announced in July, GSK confirms Boronia manufacturing site to close at end of 2022
GSK welcomes new Meningococcal B program to help protect those most at risk
Greater flexibility for Australians with severe asthma with reimbursement of at-home, self-administration delivery of NUCALA® (mepolizumab)
GSK Australia reports 2019 results (excluding Consumer Healthcare) to ASIC
Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19
Tweets from GSK Australia
-
Great to see our 2004 GSK Award for Research Excellence winner Prof. Douglas Hilton from @WEHI_research, named the… twitter.com/i/web/status/1…
yesterday
-
Our VP, Head of GSK Vaccines R&D Center, Italy, Ennio De Gregorio, explains how vaccine science can help fight anti… twitter.com/i/web/status/1…
yesterday
-
At GSK, we continue to invest in new antibiotics to tackle the risk of Antimicrobial Resistance (AMR) #WAAW20 https://t.co/FzIXvRztNw
3 days ago
